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Continuing our Classic Paper series, T E Starzllooks back at his pioneering baboon-to-human 
transplants of the 1960s. 
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A crisis followed the demonstration in 1962-1963 at the University of 
Colorado that azathioprine and 
prednisone, two immunosuppressants 
which were relatively ineffective individ-
ually, could in combination permit pro-
longed renal allograft and patient survival 
in the majority of human cases. This 
unexpected development came before 
other ingredients of an effective end-
stage renal disease program were in 
place. Only a handful of dialysis facilities 
existed in the USA. Brain death pro-
nouncement of cadaveric donors was 5 
years away, and most kidney transplant 
candidates who did not have live volun-
teer donors died while waiting. 
Xenotransplantation appeared to 
offer a way out of the dilemma. Conse-
quently, the enthusiasm ignited by Keith 
Reemtsma's kidney xenotransplant trials 
of 1963 at Tulane University in New 
Orleans was both immediate and sus-
tained. Although fierce rejection had 
destroyed a rhesus graft in a few days 
after its transplantation by Reemtsma, it 
was obvious that some of the chim-
panzee grafts might function for long 
periods. 
In ploughing new ground, Reemtsma 
already had proved that kidneys from at 
least two non-human primate donor 
species would not be abruptly rejected. 
This observation was critical. By 1963, 
Roy Caine had observed immediate kid-
ney rejection following transplantation 
between discordant species. It also had 
been learned in Colorado that hyper-
acute rejection similar to that observed 
by Caine was often triggered by isoagglu-
tinins in human recipients of ABO-mis-
matched kidney allografts. As a result of 
Reemtsma's pioneer efforts, it could be 
concluded that rhesus and chimpanzee 
kidneys would be spared this fate. 
A few weeks after Reemtsma's cases 
became public, Claude Hitchcock, Chief 
of Surgical Services, Hennapin County 
Hospital, Minneapolis, telephoned me 
with the information that a kidney from 
a third Old World primate species, the 
baboon, had also escaped hyperacute 
rejection. On 16 February 1963, Hitch-
cock had secretly engrafted a baboon 
kidney into a 65-year-old woman with an 
immediate diuresis. The gra.ft suddenly 
stopped functioning after 4 days due to 
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a hepatic arterial thrombosis, which he 
attributed to a flawed vascular anasto-
mosis. 
Hitchcock was a baboon expert, hav-
ing acquired a unique experience with 
this species during several preceding 
years in pioneer studies of auto- and 
allotransplantation of the lung, in collab-
oration with scientists attached to the 
large baboon colony at the Southwest 
Foundation for Research and Education, 
San Antonio, Texas. Fearful of public and 
professional criticism of his clinical kid-
ney case (later reported in the journal of 
the American Medical ASSOciation), Hitch-
cock had concealed its existence until 
Reemtsma's initiatives were widely 
known. 
Regretting this decision, Hitchcock 
proposed a collaboration. It was appreci-
ated that the threatened extinction as 
well as the anthropomorphic qualities of 
the chimpanzee would curtail the use of 
this animal as a donor. In contrast, the 
baboon had flourished in southern and 
central Africa and did not have such 
striking humanoid behavior. Because 
there was not yet a kidney transplant 
program in Minneapolis, the patients 
were to be treated at the University of 
Colorado, which had experience of 
nearly 50 renal allotransplantations 
under azathioprine/prednisone immune 
suppression. 
Preparation required several months 
and included on-site collaborations with 
experts in zoonoses (Dr S S Kalter 
[NIH] and his San Antonio aSSOciates) 
and primate specialists (e.g. J J Moor-
Jankowski [NIH]). many of whom also 
had worked with Reemtsma. Reemtsma. 
himself.\ was an invaluable source of 
advice. \His generosity eventually made 
possible Kendrick A Porter's classical 
histopathologic comparison of rhesus. 
baboon, and chimpanzee kidney 
xenograft rejection by human recipients. ~ 
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SUMMARY 
Six patients with terminal uremia due to 
glomerulonephritis or pyelonephritis were 
treated with heterografts from East African 
-Reproduced, with permiSSion, from Transplantation 
(196"1) 2, 752-n6 
~ Although we predicted from the 
ReemtsmalHitchcock experience that 
the baboon kidneys would not be hyper-
acutely rejected. the specter of more 
subtle antibody rejection hung heavily 
over the trials, prospectively and after-
wards. It would be another year before 
hyperacute rejection associated with 
Iymphocytotoxic antibodies was recog-
nized in ABO-compatible allograft recipi-
ents I. Consequently, a study of such 
antigraft antibodies was not done. 
Instead. attention was focused by David 
Talmage's immunology fellows (Charles 
Kirkpatrick and W E C Wilson) on the 
effect of hetero(xeno)specific hemagglu-
tinins. 
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baboons. Immunosuppressive therapy was 
provided both before and after operation 
with azathioprine and prednisone and post-
operatively local transplant irradiation and 
actinomycin C were administered intermit-
tently. The individual rejection episodes in 
the post-transplant period could be 
reversed relatively easily but these recurred 
The baboon xenografts functioned 
for a mean of 41 days when there was 
ABO compatibility (n = 3) versus 21 
days when there was not (n = 3). 
Although this suggested an important 
ABO effect, there was serologic evi-
dence that xenospecific hemagglutinins 
also bound to the transplanted kidneys 
in every case. It appeared from the clini-
cal observations, and especially from 
Porter's histopathologic analyses, that 
humoral xenograft rejection was uncon-
trollable with cell-directed immune sup-
pression, even in the phylogenetically 
close baboon-to-human combination. 
Therefore, we concluded that, "until 
improved methods of management 
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vigorously and repetitively, making it impos-
sible to relax the stringent requirements of 
antirejection therapy. The continued need 
for high-dose immunosuppressive therapy 
precipitated lethal infections in the mojority 
of cases. 
The potients lived for 19 to 98 days 
after heterotransplantation. Four died with 
the baboon kidneys still in place after 19, 
23, 35, and 49 days. In the other two 
cases the heterografts were removed after 
60 and 49 days respectively, at a time 
when urine excretion was still present, and 
homografts from volunteer convict donors 
were placed on the opposite side. Both the 
latter recipients died of septic complications 
following the second operation, after 39, 
and 44 days. Complete cessation of hetero-
graft urine excretion oppeared only in two 
cases, although renal function was failing in 
the remainder prior to death or before 
removal of the heterografts. The relation of 
the renal function to changes in the het-
eroagglutinin and hemagglutinin titers is 
described. 
After residence in the host for 19 to 60 
days, all the heterotransplants were heavily 
infrltrated with plasma cells and large lym-
phOid cells with pyroninophilic cytoplasm. 
There was also disruption of peritubular 
capillaries, interstitial edema, widespread 
tubular damage, swelling of endothelial cells 
lining arterioles, frbrinoid n~crosis of the 
walls of arterioles and interlobular arteries 
by frbrin and platelet deposits on the 
become available, further trials do not 
seem justified, and none are contemplat-
ed by us until that time". The moratori-
um lasted more than 28 years until our 
two laboratory-based attempts at 
baboon-to-human liver transplantation 
of 1992-93. These also failed because of 
a less obvious humoral rejection, but 
with unmistakable complement activa-
tion despite complete freedom from cel-
lular rejection out to 70 days. As in 
1964, the rejection of 'concordant' 
xenografts was a 'slow motion' version 
of that seen with 'discordant' 
xenografts2. It was time for a new mora-
torium. 
The humoral component of ~ 
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intima. The pre-glomerular vascular lesions 
were accompanied by focal infarcts and 
extensive interstitial hemorrhages. All the 
pathologic changes were more severe then 
those seen by Reemtsma in comparable 
series of chimpanzee-ta-man heterotrans-
plants. where cellular infrltration was slight 
and vascular lesions uncommon in the pres-
ence of major blood group incompatibility 
between donor and recipient 
During the developmental era of vascular surgery. five clinical 
renal heterotransplantations are 
known to have been tried. each with a 
different type of animal donor 
(4,7,16.19). Significant renal function was 
not obtained in any instance. and the 
longest survival was 9 days. No addi-
tional attempts at heterotransplantation 
were made in the ensuing 40 years, and 
the tacit assumption became firmly 
entrenched that such avenues of investi-
gation presented insurmountable biolog-
ic difficulties. 
In 1963, Reemtsma (12,14) and 
Hitchcock (2) and their associates re-
examined the possibility that heterograft 
function could be obtained and sus-
tained with the aid of various immuno-
suppressive agents. It was established 
that immediate urine excretion of chim-
panzee (12-14), rhesus monkey (12), 
and baboon kidneys (2) followed after 
transplantation to the human, and that 
~ xenograft rejection was discussed in our 
1964 article as an Arthus reaction, the 
same term (or alternatively 'Shwartzman 
reaction') used to described hyperacute 
allograft rejection in patients who had 
preformed antigraft cytotOXic antibodies 
(classical pathway of complement activa-
tion) but also in exceptional patients 
who were antibody free (alternative 
pathway)3. Thus, it was recognized 
almost from the beginning that humoral 
rejection of allografts under specific cir-
cumstances and that of xenografts 
involved an acute inflammatory reaction 
that would not yield to conventional 
immune suppression. 
john Najarian, in commenting 30 
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maintenance of relatively protracted 
chimpanzee heterograft function could 
be expected at least in the occasional 
case. 
The present study is an account of a 
clinical study of renal heterotransplanta-
tion carried out at the University of 
Colorado Medical Center in December. 
1963, and january, 1964. using baboons 
for donors. By comparison of the 
results with those previously obtained 
with homotransplantation (17) it was 
hoped to define the differences and sim-
ilarities of homograft and heterograft 
behavior in the human host. In addition, 
it became possible as the result of an 
exchange of functional and pathologic 
data with Reemtsma to arrive at tenta-
tive conclusions concerning the biologic 
suitability for human heterograft dona-
tion of different subhuman primates. 
Results 
Clinical course. Four patients died 
with baboon kidneys still in place Fl. In 
Cases 3 and 4, the heterografts were 
removed after 60 and 49 days respec-
tively, and homografts from volunteer 
convict donors were placed on opposite 
side. Survival after the second operation 
was 39 days in Patient 3 and 44 days in 
Patient 4. Complete cessation of het-
erograft excretion occurred only in 
Cases 2 and 5 (Table 3 [not shown]), 
although renal function was failing in the 
years later on his own classical studies'+, 
has pointed out how little progress has 
resulted from the cyclic 'rediscovery' of 
the pathogenesis of xenograft rejection, 
and of treatment strategies, using 
increaSingly sophisticated technologies 
to delineate what was already quite obvi-
ous by the late 19605. An exception to 
the futility was the recognition by Gus 
Dalmasso and Fritz Bach that the seminal 
problem of complement activation could 
be resolved by providing the target 
donor tissues with complement regula-
tory peptides of the recipient species. 
This objective was achieved when 
'humanized' transgenic animals were 
produced by David White in England and 
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remainder prior to death (Patients I 
and 6) or before removal of the trans-
plant (Patients 3 and 4). All patients 
exhibited a marked early clinical 
improvement at the time of initial diure-
sis and for varying periods thereafter. 
Recovery was, however, interrupted in 
each instance except Patient I by early 
rejection crises, which were character-
ized by transplant site tenderness. and 
by multifaceted evidence of acute renal 
failure. The timing of the rejection 
episodes is indicated in Table 4 [not 
shown] and the influence upon renal 
function is graphically portrayed in Fig-
ures 2-4 [not shown]. 
Ultimately, each of the last five cases 
became unmanageable because of the 
repetitive and closely-spaced rejections. 
Although the individual crises could be 
at least partially controlled in most 
instances, with local transplant irradia-
tion, actinomycin C or increases in 
steroid dosage, the adverse conse-
quences could not be completely 
reversed before the onset of the next 
assault. The cumulative effect was pro-
gressive deterioration, interrupted by 
incomplete remissions. In Patients 3 and 
4, removal of the heterografts was pre-
cipitated by the sudden formation of 
masses in the transplant areas, of such 
magnitude in Case 3 as to produce mas-
sive edema of the right leg which was 
apparently due to local compression of 
by john Logan in the USA with the col-
laboration of Jeffrey Platt and other col-
leagues. With this progress in cracking 
the shell of the xenotransplant problem. 
what remains to be done is the induc-
tion of organ acceptance by the same 
chimerism-dependent mechanisms that 
have spawned successful allotransplanta-
tion5• 
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